Company / Operating Cash Flow
Sarepta Therapeutics Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$205.5M
FY2025
5-year range
-$501.0M / $107.5M
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
#172 of 216
Health Care
What the data says
Sarepta Therapeutics's operating cash flow of -$205M is lower than 80% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$501M in FY2023 to $107M in FY2022.
Based on SEC 10-K filings.
-$205M in FY2025.
Improved from -$501M to -$205M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 216This company -$205.5M Sector average $658.7M
▼
-131.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 0.1% year-over-year.
- Ranks #172 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$205.5M | +0.1% |
| FY2024 | -$205.8M | +58.9% |
| FY2023 | -$501.0M | -566.2% |
| FY2022 | $107.5M | +124.2% |
| FY2021 | -$443.2M | -14.0% |
| FY2020 | -$388.7M | -67.5% |
| FY2019 | -$232.0M | +40.3% |
| FY2018 | -$388.7M | -67.5% |
| FY2017 | -$232.0M | +5.6% |
| FY2016 | -$245.8M | -64.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026